-
Results for the first quarter of 2017Oslo, Norway, 23 May 2017: Photocure ASA (OSE: PHO) today reported a Hexvix/Cysview revenue growth of 9% to NOK 36.5 million in the first quarter of 2017 (Q1 2016: NOK 33.5), with an EBITDA of NOK 4.9 million for the Hexvix/Cysview commercial franchise. The company reported a growth of 32% for the important US market, were the company recently unveiled the new growth strategy towards 2020.23 May 2017
-
1Q2017 invitation16 May 2017
-
Positive data from Phase 3 US Blue Light Cystoscopy with Cysview® study presented at AUA 2017 meeting in BostonPhotocure ASA today announced that new Phase 3 study results with Blue Light Flexible Cystoscopy (BLFC™) with Hexvix®/Cysview® were presented during a late-breaking plenary session at the American Urological Association (AUA) Annual Meeting in Boston, Massachusetts on Sunday May 14th. The study showed that BLFC with Cysview detected bladder cancer recurrence in 21.5% of the patients undergoing surveillance cystoscopy that otherwise would have been missed with white light (WL) alone, which is highly significant (p<0.0001).>0.0001).>15 May 2017
-
Phase 3 study investigating Blue Light Flexible Cystoscopy with Cysview® in surveillance setting meets primary endpoint
Oslo, Norway, May 12th, 2017: Photocure ASA (Photocure, PHO:OSE), today announced that a Phase 3 trial investigating Blue Light Flexible Cystoscopy (BLFC™) with Cysview®/Hexvix® in the surveillance setting met the study primary end point. Results from the study showed a highly statistically significant improvement (p <0.0001) in the detection of patients with recurrence of bladder cancer using blfc with cysview compared to white light (wl) alone in patients with non-muscle invasive bladder cancer (nmibc) undergoing surveillance cystoscopy. detailed data from the study will be presented during a late-breaking plenary abstract session on may 14th at the american urological association, 2017 meeting.>
12 May 2017 -
Jeremy Bahr appointed Chief Business OfficerOslo, Norway, May 5 2017: Photocure ASA (OSE:PHO), today announced the appointment of Jeremy Bahr as Chief Business Officer.05 May 2017
-
Photocure Appoints Three New Members to its Board of DirectorsOslo, Norway April, 28, 2017: Photocure ASA (OSE:PHO), a specialty pharmaceutical company and world leader in photodynamic technology for treatment of bladder cancer, today announced the appointment of Jan Hendrik Egberts,M.D., Johanna Holldack,M.D. and Gwen Melincoff to its board of directors with Dr. Egberts as the new board chairman.28 Apr 2017
-
Photocure ASA – Annual general meeting heldOslo, 27 April 2017: Photocure ASA (OSE: PHO), held its annual general meeting on 27 April 2017 at 17:00 hours (CET).27 Apr 2017
-
Late-Breaking Plenary Presentation at the AUA 2017 Annual Meeting on Blue Light Flexible Cystoscopy (BLFC™) with Hexaminolevinulate (HAL) Phase 3 StudyData on US Registry Study for BLC™ with Cysview/Hexvix will also be Presented at AUA.26 Apr 2017
-
Photocure ASA – Notice of the annual general meeting 27 April 2017Oslo, 6 April 2017: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 27 April 2017 at 17:00 hours (CET).06 Apr 2017
-
Photocure provides strategic update• Following non-conclusive partnering discussions, the company will assess further strategic alternatives for Cevira and Visonac • Company still to focus on urology franchise, with continued commitment to driving growth in United States05 Apr 2017
-
Hexvix® featured during the 2017 annual EAU congressOslo, Norway, March 29, 2017, Photocure ASA (OSE: PHO), is pleased to announce that Blue Light Cystoscopy (BLC™) with Hexvix® was featured during the European Association of Urology (EAU) annual meeting held in London, UK, March 24th - 28th. The EAU is one of the largest international meetings in urology, attended by more than 12,000 urologists from over 110 countries.29 Mar 2017
-
Results for fourth quarter and full year 2016Oslo, Norway, 15 February 2017: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a revenue growth of 10 % to NOK 38.1 million in the fourth quarter of 2016 (Q4 2015: NOK 34.5), with an EBITDA of NOK 10.7 million for the Hexvix/Cysview commercial franchise. Full year 2016 revenues ended at NOK 143.6 million (134.7). Photocure targets revenues from the US operations to quadruple to a range of USD 15 million by 2020.15 Feb 2017
-
A better future for patients with bladder cancer using advanced technologies includes a vital role for Blue Light Cystoscopy with Hexvix®/Cysview®Oslo, Norway, February 8th 2017, Photocure ASA announced today a publication in the Scandinavian Journal of Urology, describing a vision for improving outcomes for patients with non-muscle-invasive bladder cancer (NMIBC), and the significant role that blue light cystoscopy (BLC) with Hexvix® plays in achieving it.08 Feb 2017
-
Presentation of the fourth quarter and full year 2016 resultsPhotocure will present its fourth quarter and full year 2016 report on Wednesday 15 February 2017 at Hotel Continental, Oslo, Norway.07 Feb 2017
-
Photocure Completes Enrollment in US Market expansion study of Blue Light Flexible Cystoscopy (BLFC) with Cysview®Oslo, Norway, February 3, 2017 Photocure ASA (OSE: PHO), announced today that it has completed enrollment in its Phase 3 study with BLFC with Cysview in patients with Non Muscle Invasive Bladder cancer (NMIBC) undergoing follow up (surveillance) cystoscopy in the outpatient setting. The enrollment of 300 bladder cancer patients has secured that a minimum of 100 patients have been referred to and received repeat administrations of Blue Light Cystoscopy with Cysview in the operating room setting. In the study, Cysview was used in conjunction with the flexible KARL STORZ system. Results from the study are expected to be available mid-2017.03 Feb 2017
-
Innovative Technology Designation for Blue Light CystoscopyBlue Light equipment supplier and Photocure partner KARL STORZ Endoscopy-America, Inc. announced its system for performing Blue Light Cystoscopy with Cysview® (BLCC) has received an Innovative Technology designation from Vizient, Inc.11 Jan 2017
-
Photocure to present at investor meetings in San FranciscoPhotocure ASA (OSE: PHO) management is this week conducting investor meetings in San Francisco (US) in connection with the J.P. Morgan healthcare conference.09 Jan 2017
-
US registry shows that Blue Light Cystoscopy (BLC) with Cysview®/Hexvix® leads to improved detection and classification of bladder cancerOslo, Norway, December 5, 2016 Photocure ASA (PHO-NO) announced today new data from a prospective multicenter real world study that included 338 patients, 415 BLC procedures and 1060 lesions from nine study sites in the United States. BLCC as an adjunct to white light cystoscopy (WLC) resulted in the detection of an additional 151 lesions and 45 patients uniquely with the addition of blue light. This resulted in upgrading or upstaging of 52 (15%) of the patients. Correct staging and grading impacts the management of bladder cancer patients and may have an impact on patient outcomes.05 Dec 2016